Risk and promise: an 11-year, single-center retrospective study of severe acute GVHD in pediatric patients undergoing allogeneic HSCT for nonmalignant diseases

• Príomhchruthaitheoirí: Irina Zaidman (Údar), Ehud Even-Or (Údar), Elroee Aharoni (Údar), Dina Averbuch (Údar), Yael Dinur-Schejter (Údar), Adeeb NaserEddin (Údar), Mordechai Slae (Údar), Bella Shadur (Údar), Polina Stepensky (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Frontiers Media S.A., 2023-05-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

BackgroundHematopoietic stem cell transplantation (HSCT) is the only curative option for many nonmalignant hematopoietic-derived diseases in pediatric patients. Survival after HSCT has improved in recent years and resulted in a 90% survival rate and cure in some nonmalignant diseases. Graft-vs.-host...